Nature Communications (Mar 2024)

NMR and MS reveal characteristic metabolome atlas and optimize esophageal squamous cell carcinoma early detection

  • Yan Zhao,
  • Changchun Ma,
  • Rongzhi Cai,
  • Lijing Xin,
  • Yongsheng Li,
  • Lixin Ke,
  • Wei Ye,
  • Ting Ouyang,
  • Jiahao Liang,
  • Renhua Wu,
  • Yan Lin

DOI
https://doi.org/10.1038/s41467-024-46837-0
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 17

Abstract

Read online

Abstract Metabolic changes precede malignant histology. However, it remains unclear whether detectable characteristic metabolome exists in esophageal squamous cell carcinoma (ESCC) tissues and biofluids for early diagnosis. Here, we conduct NMR- and MS-based metabolomics on 1,153 matched ESCC tissues, normal mucosae, pre- and one-week post-operative sera and urines from 560 participants across three hospitals, with machine learning and WGCNA. Aberrations in ‘alanine, aspartate and glutamate metabolism’ proved to be prevalent throughout the ESCC evolution, consistently identified by NMR and MS, and reflected in 16 serum and 10 urine metabolic signatures in both discovery and validation sets. NMR-based simplified panels of any five serum or urine metabolites outperform clinical serological tumor markers (AUC = 0.984 and 0.930, respectively), and are effective in distinguishing early-stage ESCC in test set (serum accuracy = 0.994, urine accuracy = 0.879). Collectively, NMR-based biofluid screening can reveal characteristic metabolic events of ESCC and be feasible for early detection (ChiCTR2300073613).